Latest news


Second quarter and first half 2019 results

Posted on Aug 28, 2019

Oslo (Norway), 28 August 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its second quarter and first half 2019 result. Please find enclosed the report and presentation. First patient enrolled into the pivotal fimaCHEM “RELEASE” study, successful clinical proof-of-concept of fimaVACC and extension of the fimaNAc collaboration with a large […]

Invitation to second quarter and first half 2019 results presentation

Posted on Aug 20, 2019

Oslo, Norway, 20 August 2019 – PCI Biotech invites to a presentation of the company’s second quarter and first half 2019 results on Wednesday 28 August 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 28 August, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation […]

Extension of preclinical research collaboration agreement with a top-10 large pharma company

Posted on Jul 22, 2019

Oslo (Norway), 22 July 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company. The pharma company is one of the global leaders in nucleic acid therapeutics and the collaboration was initiated in September 2015. The aim of […]